Kaseb, A. O., Shindoh, J., Patt, Y. Z., Roses, R. E., Zimmitti, G., Lozano, R. D., Hassan, M. M., Hassabo, H. M., Curley, S. A., Aloia, T. A., Abbruzzese, J. L., & Vauthey, J. (2013). modified cisplatin/interferon α‐2b/doxorubicin/5‐fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer, 119(18), 3334–3342. http://access.bl.uk/ark:/81055/vdc_100025043991.0x00003e